Navigation Links
Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
Date:5/13/2013

THE WOODLANDS, Texas, May 13, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands , M.D., Ph.D., president and chief executive officer, will present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 3:00 PM PDT (6:00 PM EDT) in Las Vegas, Nevada. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until June 15, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results
2. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
3. Lexicon to Report First Quarter Financial Results on May 10, 2013
4. Lexicon To Present At The Needham Healthcare Conference
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results
6. Lexicon To Present At The BIO CEO & Investor Conference
7. Lexicon Pharmaceuticals To Present At The Piper Jaffray Annual Healthcare Conference
8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Third Quarter Results
9. Lexicon to Provide Third Quarter 2012 Financial Results
10. Lexicon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Mass. , Dec. 9, 2016 MSD, ... and supply chain solutions to alternate site health care ... with First Choice Medical Supply ("First Choice"), a privately ... servicing the skilled nursing and home health segments. We ... family. This compelling transaction will deliver ...
(Date:12/9/2016)... 2016   Hudes Laser Aesthetica announced ... multi-wavelength Astanza Trinity laser and Astanza Liberty IPL ... tattoo removal, IPL hair removal, pigmented and vascular ... Laser Aesthetica is setting high standards for aesthetic ... promises to deliver effective, long-lasting results. ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... forecasts the global optical transceiver market to grow at a CAGR ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the shipment of optical transceivers ...
Breaking Medicine Technology:
(Date:12/10/2016)... WASHINGTON, D.C. (PRWEB) , ... December 10, 2016 ... ... children’s Christmas wish lists for Santa are all sources of external stimuli that ... season. For some, the added pressure to spread holiday cheer through gifts, food ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... aural rehabilitation—provided by audiologists—to remain a critical part of public access to hearing ... Administration (FDA) announced this week that, starting immediately, it would no ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
Breaking Medicine News(10 mins):